ea0089c4 | Clinical – Chemo/SSA/Biologics | NANETS2022
McLaughlin Nicole
, McGarrah Patrick
, Eiring Rachel
, Leventakos Konstantinos
, Sonbol Mohamad
, Starr Jason
, Hobday Timothy
, Halfdanarson Thorvardur
Background: Extrapulmonary PD NECs carry a poor prognosis. Some studies suggest cisplatin is more appropriate for younger patients due to its increased potency and nephrotoxicity compared to carboplatin, but randomized trials are lacking. We aim to determine whether there is a difference in outcomes for cisplatin vs carboplatin while adjusting for possible confounding factors.Methods: We identified PD NEC patients at Mayo Clinic between 2000-2022. Kaplan...